



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of) Examiner: Unknown
McDonnell, et al.)
Serial No.: 10/637,149) Art Unit: Unknown
Filed: August 8, 2003) Confirmation No.: 3426
For: DECONTAMINATION OF)
PRION-CONTAMINATED)
SURFACES WITH PHENOLS)
Attorney Docket No.:) Cleveland, OH 44114
MEDZ 2 01304) February 10, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§1.56, 1.97, 1.98 and MPEP §609, applicant(s) submit(s) the following Disclosure Statement concerning art of which the applicant(s) is (are) aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Under §1.98(a)(3), no concise explanation of relevance is required for information that is in the English language. Accordingly, the enclosed require(s) no further explanation (or no translation is available).

Consideration of the appropriate paragraph(s) indicated below is respectfully requested:

WITHIN THREE MONTHS OF FILING: Under § 1.97(b)(1), this Information Disclosure Statement is being filed within three months of the filing date of the application. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

BEFORE FIRST OFFICE ACTION: Under § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

INTERNATIONAL SEARCH REPORT: Under § 1.97(e)(1), the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

BEFORE FINAL ACTION/WITH FEE: Under § 1.97(c)(2), this information shall be considered if filed before the mailing date of a final action if accompanied by a fee in the amount of \$180.00 as required by § 1.17(p). Accordingly, the necessary fee accompanies this Information Disclosure Statement. Any overpayment or deficiency can be charged to Deposit Account No. 06-0308.

PRIORITY CLAIM: The attached PTO 1449 Form includes all patents, publications, or other information previously cited by or submitted to the Office in one or more prior applications from which the present application


claims priority. These one or more prior applications are identified in the papers accompanying the filing of this application. In accordance with §609 MPEP, only copies of art not previously submitted are enclosed.

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.


Respectfully submitted,

**FAY, SHARPE, FAGAN,
MINNICH & MCKEE, LLP**

10 Feb 2004
Date


Thomas E. Kocovsky, Jr.

Reg. No. 28,383


Ann M. Skerry, Reg. No. 45,655
1100 Superior Avenue, 7th Floor
Cleveland, OH 44114-2518
216/861-5582

CERTIFICATE OF MAILING


I certify that this Information Disclosure Statement and accompanying document(s) are being


deposited with the United States Postal Service as First Class mail under 37 C.F.R. 1.8, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

transmitted to facsimile number under 37 C.F.R. 1.8 on the date indicated below.

deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated below and is addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail Label No.:
Date
February 12, 2004

Signature

Printed Name
Cheryl M. Kobylnski



Substitute for form 1449/PTO

FEB 17 2004

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**
(Use as many sheets as necessary)

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	10/637,149	
Filing Date	August 8, 2003	
First Named Inventor	McDonnell, et al.	
Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket No.	MEDZ 2 21304	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No. Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number Kind Code (if known)				
	AM					
	AN					
	AO					
	AP					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T
	AQ	Antiloga, et al. "Prion Disease and Medical Devices", ASAIO Journal, V. 46, N. 6, 2000; pp. S69-S72 XSP001092854	
	AR	Darbord, "Inactivation of Prions in Daily Medical Practice", Biomedicine & Pharmacotherapy, V. 54, 1999 pp. 34-38 XP002228686	
	AS	Rutala, et al., "Creutzfeld-Jakob Disease: Recommendations for Disinfection and Sterilization", Clinical Infectious Diseases, V. 32, N. 9, May 2001 pp. 1348-1356 XP008012867	
	AT		
	AU		
	AV		

Examiner Signature	Date Considered
--------------------	-----------------